iQemo: Enabling Safe Management of Anaphylaxis and Hypersensitivity Reactions in SACT

The recent publication from the UK SACT Board, “Anaphylaxis and Hypersensitivity Reactions: Guidance for the management of adults receiving intravenous systemic anti-cancer therapy (SACT) for the treatment of solid tumours” (Version 1, 8^th August 2025) outlines best practice for managing anaphylactic and hypersensitivity reactions. These incidents, though rare, demand swift recognition, clinical coordination, and accurate documentation.

iQemo is fully equipped to support the delivery of this guidance. Its design ensures SACT teams can safely manage hypersensitivity risks at every stage from prescribing and preparation through to administration, emergency response, and documentation.

Allergies & Adverse Reactions

iQemo provides structured functionality for recording drug allergies and adverse reactions. To do this, users can:

• Select the implicated drug from the formulary

• Record the reaction severity

• Add free-text clinical context where appropriate

Allergy alerts and adverse event information is then prominently flagged across the patient record, treatment course, and prescription interfaces. These warnings act as critical safety guards at prescribing, screening, and administration stages.

Support Drugs and Emergency Medications

The UK SACT Board guidance highlights the need for emergency medications such as adrenaline, corticosteroids, and antihistamines to be readily available during SACT administration.

iQemo provides the ability to:

• Configure prophylactic and emergency medications within regimen templates

• Create prophylactic and emergency drug sets for standardised and easier regimen configuration

• Create prophylactic and emergency drug sets for standardised and easier prescription additions

This ensures that both prophylactic and reactive medications are visible to prescribers and nurses at the point of care.

Prescribing Messages and Clinical Prompts

For drugs commonly associated with infusion-related reactions (e.g. oxaliplatin, irinotecan, rituximab), iQemo enables clear communication of regimen-specific precautions depending on the configuration of the regimen. Prescribing teams can be presented with:

• Treatment course or cycle-specific prescribing messages

• Treatment day specific instructions, warnings and information

• Drug-specific administration and monitoring instructions

These prompts are part of iQemo’s standard regimen configuration options and ensure national best practice is reinforced during prescribing.

Pre-Administration Checks

Prior to administering any SACT, iQemo guides nurses through structured pre-administration checks. These checks can include:

• Confirming patient identity using barcode scanning

• Documenting current weight and performance status

• Verifying clinical assessment requirements and allergy status

These checks are mandatory and must be completed before drug administration is permitted, providing assurance that treatment is reviewed for safety compliance.

Real-Time Capture of Reaction Events

In the event of a suspected anaphylactic or hypersensitivity reaction, iQemo provides a complete workflow for:

• Stopping or cancelling drug lines

• Recording clinical observations and interventions

• Documenting which drugs were not administered and why

• Adding notes and clinical commentary for multidisciplinary follow-up

Reaction entries remain visible throughout the patient’s care, forming part of the permanent record to inform future prescribing decisions.

‍

Documentation and Governance

The UK SACT Board guidance stresses the importance of clear, contemporaneous documentation following a reaction. iQemo’s built-in tools support this by:

• Automatically capturing administration outcomes

• Logging dose interruptions and reasons

• Providing visibility of adverse event records

All actions are timestamped and user-attributed, ensuring compliance with documentation requirements and enabling retrospective review.

Conclusion

The functionality required to deliver the UK SACT Board’s Anaphylaxis and Hypersensitivity Reactions Guidance is already embedded within iQemo. From the moment a patient is prescribed treatment, through to administration and beyond, iQemo supports clinical teams in managing risk, documenting events, and ensuring the safest possible experience for SACT patients. Organisations using iQemo are equipped to meet national standards, by design.

‍

‍